Holen Sie sich die Stockscreener-App
2.45
6.13%
-0.16
Handel nachbörslich:
2.48
0.03
+1.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.61
Offen:
$2.65
24-Stunden-Volumen:
9.60M
Relative Volume:
0.68
Marktkapitalisierung:
$972.57M
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-1.9919
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
-2.78%
1M Leistung:
+8.89%
6M Leistung:
+23.12%
1J Leistung:
-65.83%
1-Tages-Spanne:
$2.44
$2.7199
1-Wochen-Bereich:
$2.41
$2.80
52-Wochen-Spanne:
$1.6385
$7.025
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.45 | 1.04B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance - The Globe and Mail
Why Iovance Biotherapeutics Inc. stock appeals to dividend seekersWeekly Stock Analysis & Accurate Intraday Trading Signals - ulpravda.ru
Iovance Biotherapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Iovance Biotherapeutics Inc. stock remains resilientJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - ulpravda.ru
Why retail investors favor Iovance Biotherapeutics Inc. stockMarket Entry Points & Exceptional Return Growth - ulpravda.ru
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - MSN
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1%Here's What Happened - MarketBeat
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Insider Monkey
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Will Iovance Biotherapeutics Inc. stock attract more institutional investorsCovered Call Writing & Budget Friendly Investment Plans - bollywoodhelpline.com
Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge? - Sahm
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025) - ts2.tech
Iovance Biotherapeutics: Is it Time to Invest? - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7%Still a Buy? - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
Will Iovance Biotherapeutics Inc. stock outperform Nasdaq indexTrade Analysis Summary & Community Verified Trade Signals - ulpravda.ru
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Iovance Biotherapeutics Inc. stock attracts high net worth investors - DonanımHaber
How Iovance Biotherapeutics Inc. (2LB) stock valuation compares with sectorGap Down & Weekly High Return Stock Opportunities - DonanımHaber
Iovance Biotherapeutics (IOVA): Assessing Valuation After FDA Progress, Melanoma Data and Upgraded Analyst Targets - Sahm
Market Trends: Is Iovance Biotherapeutics Inc. (2LB) stock cheap vs fundamentalsMarket Activity Report & Weekly High Return Forecasts - Улправда
There Is A Reason Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Price Is Undemanding - 富途牛牛
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch - ts2.tech
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics Tries To Deliver On Cell Therapy Hopes - Finimize
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation - Nasdaq
Barclays Doubles Iovance Biotherapeutics’ Price Target in Bold Market Move - StocksToTrade
Iovance Biotherapeutics (IOVA) Sees Raised Price Target by Barcl - GuruFocus
Iovance Biotherapeutics Advances Innovative Melanoma Treatment with Updated Study - TipRanks
Barclays’ Bullish Outlook Sparks Iovance Stock Surge - timothysykes.com
Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7%Should You Buy? - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
114,198 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,516 |
0 |
107,530 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
108,478 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
468,948 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 01 '25 |
Option Exercise |
0.00 |
41,669 |
0 |
476,232 |
| Puri Raj K. | Chief Regulatory Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
218,326 |
| Vogt Frederick G | Interim CEO & General Counsel |
Sep 02 '25 |
Option Exercise |
0.00 |
52,086 |
0 |
456,690 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):